NCT03553602 2026-01-29
BEACON
Loyola University
Phase 1/2 Terminated
Clinical Trials
48 trialsNCT05617040 2025-11-10
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Barinthus Biotherapeutics
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03843918 2025-09-10
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
Laekna Limited
Phase 1/2 Terminated
NCT05633160 2025-08-29
COMBAT
Clarity Pharmaceuticals Ltd
Phase 1/2 Terminated
NCT03712371 2025-06-10
Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients
Medical University of South Carolina
Phase 1/2 Terminated
NCT04556617 2025-04-08
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Opna Bio LLC
Phase 1/2 Terminated
NCT06257758 2025-03-17
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Valerio Therapeutics
Phase 1/2 Terminated
NCT05075577 2025-02-28
EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC
ESSA Pharmaceuticals
Phase 1/2 Terminated
NCT05917470 2024-12-11
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
Oncternal Therapeutics, Inc
Phase 1/2 Terminated
NCT00321698 2024-08-29
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Terminated
NCT06065059 2024-08-13
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT05553639 2024-06-12
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
Hookipa Biotech GmbH
Phase 1/2 Terminated
NCT03577028 2024-02-14
Study of HPN424 in Patients With Advanced Prostate Cancer
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Terminated
NCT00633087 2023-12-22
2-Deoxyglucose
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT03837353 2023-12-18
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
NYU Langone Health
Phase 1/2 Terminated
NCT04737109 2023-11-13
ADDItion
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT01093183 2023-09-13
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
University of Nebraska
Phase 1/2 Terminated
NCT05489991 2023-08-18
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Tceleron Therapeutics, Inc.
Phase 1/2 Terminated
NCT04424641 2023-07-25
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Terminated
NCT03367819 2022-05-16
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT02913131 2022-04-22
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
University of California, San Francisco
Phase 1/2 Terminated
NCT03441464 2022-02-25
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
Lumicell, Inc.
Phase 1/2 Terminated
NCT02565901 2021-10-01
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of Washington
Phase 1/2 Terminated
NCT03545165 2021-08-24
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT02805894 2021-05-10
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
Nanobiotix
Phase 1/2 Terminated
NCT03323879 2021-04-27
Delight
Sunnybrook Health Sciences Centre
Phase 1/2 Terminated
NCT03572478 2021-03-09
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
University of Chicago
Phase 1/2 Terminated
NCT03741712 2021-02-05
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Terminated
NCT01163084 2019-02-28
Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00924807 2018-12-11
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
Beth Israel Medical Center
Phase 1/2 Terminated
NCT01335204 2018-07-13
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Medical University of South Carolina
Phase 1/2 Terminated
NCT02606123 2018-03-01
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
ESSA Pharmaceuticals
Phase 1/2 Terminated
NCT00536991 2017-06-14
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT02483884 2017-03-22
PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
Life Molecular Imaging SA
Phase 1/2 Terminated
NCT01817738 2017-02-17
Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer
CureVac
Phase 1/2 Terminated
NCT00879619 2017-02-01
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
University of California, Irvine
Phase 1/2 Terminated
NCT00861471 2016-06-30
Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer
NYU Langone Health
Phase 1/2 Terminated
NCT00503984 2016-06-09
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
University of Miami
Phase 1/2 Terminated
NCT02042885 2015-10-20
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Otsuka Novel Products GmbH
Phase 1/2 Terminated
NCT00539968 2015-02-05
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00753220 2014-11-04
CRITICAL
Bostwick Laboratories
Phase 1/2 Terminated
NCT00005072 2014-07-29
Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer
Vical
Phase 1/2 Terminated
NCT00293371 2012-10-11
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
University of California, San Francisco
Phase 1/2 Terminated
NCT00471718 2012-07-11
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated
NCT01132404 2012-01-31
Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
Millennium Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT00050687 2011-01-28
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
Titan Pharmaceuticals
Phase 1/2 Terminated
NCT00132756 2006-11-08
Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer
Morton Plant Mease Health Care
Phase 1/2 Terminated